Autoimmune diseases are body’s unusual immune reaction that produce antibodies which attack own tissues and cells. This usually causes destruction and weakening of healthy tissues. There are almost 80 types of autoimmune diseases existing in the world which includes rheumatoid arthritis or systemic lupus erythematosus. Auto antibody test, complete blood count, antinuclear antibody test, erythrocyte sedimentation rate and C-reactive protein are some of the tests used for diagnosis of the autoimmune disease. The report provides analysis of global autoimmune disease diagnostics market for the period 2016-2026, wherein 2018 to 2026 is the forecast period and 2017 is considered as the base year. According to Acumen Research and Consulting, the global autoimmune disease diagnostics market is expected to grow at significant CAGR around 2.8% throughout the forecast period and reach around US$ 16 billion by 2026.
Increasing occurrences of diseases, growing demand for better and accurate diagnostic procedures, rising awareness towards the benefits of early diagnosis, various research and development activities, and initiatives taken by favourable governments regulations are some of the key factors that are fueling the autoimmune disease diagnostics market growth across the globe. Rising occurrences of various diseases such as Hashimoto’s thyroiditis, rheumatoid arthritis and various initiatives taken by favourable governments are some of the fundamental factors driving the global autoimmune disease diagnostics market growth. According to the American Autoimmune Related Diseases Association, around 50 million people from the region are presently suffering from autoimmune related disorders. This factor is anticipated to create immense opportunities for the global autoimmune disease diagnostics market over the forecast period. Several initiatives in order to decrease the cost required to cure these diseases is also anticipated to supplement the overalls market growth during the forecast period. Furthermore, rapidly increasing occurrences of various diseases along with the growing awareness amongst the patients is the key factor that positively impacting the growth of the segment. Development of healthcare infrastructure with the rising expenditure is expected to boost the demand for the various enhanced diagnostic methods for better treatment. The growing demand for improved and accurate diagnostic procedures due to the growth in prevalence of the various diseases is projected to boost the adoption of autoimmune disease diagnostics methods throughout the forecast period. In order to develop superior diagnosis and treatment methods the wide-ranging research and development activities are supported by government. Such research activities are expected to further spur the overall market growth. American Autoimmune Related Diseases Association has also taken the large number of initiatives in order to increase the awareness towards the advantages of early diagnosis. However, lack of skilled professionals in healthcare industry and complex and long process for diagnosis of autoimmune disease are some of the major factors that may hamper the growth of the autoimmune disease diagnostics market globally.
Autoimmune Disease Diagnostics Market by Product
Global Autoimmune disease diagnostics Market, by Geography
The market research study on “Autoimmune Disease Diagnostics Market (By Product: Systemic [Rheumatoid arthritis diagnostics, Ankylosing spondylitis diagnostics, Systemic lupus erythematosus diagnostics, Others], Localized) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026” offers detailed insights on global autoimmune disease diagnostics market segments with market dynamics and their impact. The report provides insights on global autoimmune disease diagnostics market by product and major geographic regions. The report also covers basic technology development policies.
The global autoimmune disease diagnostics market is characterized by the presence of experienced and established players. Some of the key players include AstraZeneca, Inova Diagnostics Inc., Novartis AG, Abbott Laboratories, Pfizer Inc., F. Hoffmann-La Roche, Bio-Rad Laboratories Inc., Hemagen Diagnostics Inc., Beckman Coulter Inc. and Sanofi-aventis.